Epalinges, Switzerland, April 25, 2019 – Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life disabling human diseases has learned that there is inaccurate information in the public domain.
Mymetics is dedicated to develop vaccines for life threatening and disabling diseases based on our virosome virus like particle platform.
One of the important efforts by Mymetics is the aim to develop a safe and highly efficacious vaccine which is cold chain independent and can address all the stages of the plasmodium falciparum parasite.
Mymetics can only do this through its multiple partnerships with academic institutions and NGOs, like the Swiss Public Health and Tropical Institute, University of Basel, University of Lausanne, University of Oxford, the European Vaccine Initiative, the Laboratory for Malaria Immunology and Vaccinology (LMIV), the NIH and PATH-MVI to name a few.
The current status is the development of a tetra-valent (containing four malaria antigens) virosome based vaccine that addresses the blood and liver stage of the pf parasite. These formulations are being tested in well know pre-clinical animal models and results are expected later in 2019.
For World Malaria Day, we recently worked with Mediaplanet UK on the 2019 Fight against Malaria Campaign. A printed publication was enclosed within every copy of The Guardian newspaper and the content available online also at www.fightagainstmalaria.com.
Read exclusive content from key thought leaders and learn more about the importance of stepping up commitment and investment to end malaria.